ProKidney: Slow-Burning 'Buy' Opportunity Based On 2027 Approval Of Kidney Disease Therapy

ProKidney shows strong Phase 2 CKD data, FDA support, and cash runway, with key readouts ahead despite single-asset risks. See why PROK stock is a buy.